Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVE-4 long-term follow-up of YCANTH for common warts
jRCT2031250704Phase 3Recruiting
- Sponsor
- Torii Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of cantharidin in common wart, sponsored by Torii Pharmaceutical. Primary endpoints: Incidence and severity of adverse events including local skin reactions, Change from baseline in vital signs and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
cantharidin
03
Conditions
common wart
Beyond the preview
Go deeper on jRCT2031250704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250704.